Enter your Email Address


Useful Links

Know What The Insiders Are Doing!
Stock Trading Software

More Links




[Most Recent Quotes from www.kitco.com]

[Most Recent Quotes from www.kitco.com]




PWRM, ATU, AQNM, DSCO, TSTR, CHIP, DrStockPick.com Stock Report!

Dr. Stock Pick (September 30th, 2009) Writes:

Dr Stock Pick HOT News & Alerts!

_________________________________________

drstock-2-3

FREE Daily Stock Alerts From DrStockPick.com

signup3m

_________________________________________

Wednesday September 30, 2009

DrStockPick.com Stock Report!

PWRM, ATU, AQNM, DSCO, TSTR, CHIP

**************************************************************

PWRM, Power 3 Medical Products Inc, PWRM.OB

Power3 Medical Products, Inc. is a leading bio-medical company engaged in the commercialization of neurodegenerative disease and cancer biomarkers, pathways, and mechanisms of diseases through the development of diagnostic tests and drug targets. Power3’s patent-pending technologies are being used to develop screening and diagnostic tests for the early detection and prognosis of disease, identify protein biomarkers, and drug targets. Diagnostic tests are targeted toward markets with critical unmet needs in areas including neurodegenerative disease (NuroPro) and breast cancer (BC-SeraPro). Power3 expects to

...
Tags for this Post:
Actuant Corporation, Actuation Systems, advertisement services, ALS, Aquentium Inc.;, AT&T Inc., ATU, Beijing, Biotechnology, Breast Cancer, broker, Canada, cancer, Chair and Keynote Speaker, Chemicals, chief scientific officer, China, Congress, Crown Equity Holdings Inc.;, diagnostic tests, Discovery Laboratories Inc;, Discovery Labs, Dr Stock Pick, Dsco, e-coli, equity trader, Fda, Food Processors, green technologies;, Houston, improved food safety standards, industrial products, integrated satellite, integrated satellite wireless communications, International Congress, Internet Protocol, Investing Lessons, Ira Goldknopf, KL4 Surfactant Technology, mobile communication services, neurodegenerative disease;, non-chemical process;, non-chemical processing, non-chemical sanitation equipment, non-chemical technology, North America, Phase Ii, Power 3 Medical Products Inc., Power3 Medical Products Inc.;, Power3;, president, prevention of respiratory distress syndrome;, professional investment analyst and consultant, public relations services, RECEPTORS LLC;, sanitation equipment, satellite phone, selective binding products, stock featured on our site;, Stock Pick, Stocks to Watch, Surfaxin(R) (lucinactant), Technology, TerreStar Corporation, TerreStar Networks Inc., terrestrial communications network, Texas, Therapies for respiratory diseases, U.S. Food and Drug Administration, United States, United States Food and Drug Administration, VeriChip Corporation, wireless communications, www.aquentium.com, www.crowntradingsystems.com, www.crwenews.com, www.drstockpick.com, www.power3medical.com, www.stock-ir.com

DSCO, HTDS, DrStockPick.com Watch List! for Tuesday September 15, 2009, Discovery Laboratories Inc. and Hard to Treat Diseases

Dr. Stock Pick (September 14th, 2009) Writes:

 

DSCO, Discovery Laboratories Inc.

HTDS, Hard to Treat Diseases

DrStockPick Watch List! drstock

 

DrStockPick.com Watch List! for Tuesday September 15, 2009

signup3m

 

My Picks for Tuesday September 15, 2009 are:

**************************************************************

DSCO, Discovery Laboratories Inc.

DSCO is a biotechnology company committed to the development and commercialization of novel Surfactant Replacement Therapies (SRTs™) with potential application across the respiratory disease continuum. Surfactant is produced naturally in the lungs and is essential for normal breathing throughout life.

DSCO’s product platform is based on a novel pulmonary surfactant technology intended to establish a completely new, therapeutic approach in the treatment of respiratory disease, with a targeted initial application in

...

Discovery Labs Drifting Lower

Mike Havrilla (July 3rd, 2008) Writes:

Shares of Discovery Labs (DSCO) have been drifting lower in recent trading and now are at the $1.55 level, which is a nice entry point for a long position for speculative biotech investors. Since meeting with the FDA in mid-June, DSCO has trended lower on investor disappointment that the Company would delay its response to the most recent approvable ruling for Surfaxin until September. However, the Company still expects a Class I review (60 days), which could result in approval for Surfaxin by late November or early December without the need for additonal clinical trials. Summer is typically a slow time for biotech trading and provides a good time to accumulate shares ahead of a Fall catalyst.


Newsletter

No recommendations, either expressed or implied, are being made to buy, sell, hold or short any of the mentioned stocks. No legal, tax or accounting advice is expressed or implied. Always contact your attorney, CPA, or tax advisor before acting on any legal or tax issues. StraightStocks.com is not responsible for the content, products, or services of any of the advertisers on this site. StraightStocks.com receives compensation from advertisers on this blog. Services and products referred to herein are trademarks, registered trademarks, servicemarks, and/or registered servicemarks of their respective trademark or servicemark owners.